


Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

#### Data Insights: Covid-2019 Monitor


Thursday, March 17, 2022



#### For more information contact us: Donald Luskin: 214 550 2121 <u>don@trendmacro.com</u>

Thomas Demas: 704 552 3625 tdemas@trendmacro.com


Copyright 2022 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations


| Rolling                 | out th                    | e vacc                 | ines in       | the US             | S and t   | he wor      | ld                  |                |                   |           |           |       |
|-------------------------|---------------------------|------------------------|---------------|--------------------|-----------|-------------|---------------------|----------------|-------------------|-----------|-----------|-------|
| Administered Cumulative |                           |                        |               |                    |           |             | То                  | day            | Immunity          | Full      | Partial   |       |
| Doses                   | loses 572,648,576         |                        | 72,648,576    |                    |           |             |                     | +0.120         | million           | US        | 65.3%     | 76.7% |
| Boosters                |                           | 97,492,539             |               |                    |           |             | +0.047 million      |                | UK                | 72.2%     | 77.3%     |       |
|                         |                           | One                    | One dose      |                    | % Pop Imr |             | <b>% pop</b><br>67% | New imm        | une today         | France    | 77.8%     | 80.1% |
| Total popul             |                           |                        | 62,399,377    | 79%                | 2         | 223,059,115 |                     | +0.031 million |                   | Spain     | 85.2%     | 87.9% |
| -                       | Age 12 to 17              |                        | 17,457,205    |                    |           | 14,883,741  | 59%<br>74%          | +0.004 million |                   | Germany   | 75.1%     | 75.8% |
|                         | 0                         |                        | 76,809,732    | 87%                | 1         | 149,935,398 |                     | +0.017 million |                   | Italy     | 79.1%     | 84.0% |
| Age 65 and              | Age 65 and over 58,266,48 |                        | 58,266,489    | 100%               |           | 50,430,536  | 92%                 | +0.003 million |                   | Australia | 80.7%     | 85.9% |
| ۲&۲                     |                           |                        |               |                    |           |             |                     |                |                   | Israel    | 65.9%     | 72.1% |
| 0%                      |                           |                        |               |                    |           |             |                     |                |                   | Canada    | 81.6%     | 85.8% |
| Moderna                 | St.                       | State                  |               |                    |           |             |                     |                | Japan             | 79.7%     | 81.0%     |       |
| Pfizer<br>c10/          |                           |                        | 110           | Best               |           |             |                     |                |                   | Africa    | 14.2%     | 19.7% |
|                         |                           |                        | tial immunity | Midd               | lo        |             |                     |                |                   | India     | 58.6%     | 69.6% |
|                         |                           |                        | •             | Wildle             |           |             |                     |                |                   | Brazil    | 74.0%     | 84.1% |
| Full initiality         |                           |                        |               | Worst              |           |             |                     |                | China             | 85.8%     | 88.1%     |       |
| AK                      |                           | as % population        |               |                    |           |             |                     |                | Global data diffe |           | s, timing |       |
| 69.0%                   |                           | "Immunity" = two doses |               | <b>WI</b><br>71.3% |           | WI          | As of Mar 16        |                |                   |           | ME        |       |
| 61.4%                   |                           |                        |               |                    |           |             |                     |                |                   |           | 89.3%     |       |
|                         |                           |                        |               |                    | -         | 64.9%       |                     | •              |                   |           | 78.6%     |       |
|                         | WA                        | ID                     | MT            | ND                 | MN        | IL          | MI                  |                | NY                | VT        | NH        |       |
|                         | 80.1%                     | 60.5%                  | 64.7%         | 64.6%              | 74.6%     | 76.3%       | 66.5%               |                | 89.3%             | 92.7%     | 95.0%     |       |
|                         | 71.8%                     | 53.4%                  | 56.2%         | 54.6%              | 68.6%     | 67.9%       | 59.6%               |                | 75.9%             | 80.4%     | 69.5%     |       |
|                         | OR                        | NV                     | WY            | SD                 | IA        | IN          | OH                  | PA             | NJ                | MA        |           |       |
|                         | 77.2%                     | 74.4%                  | 58.2%         | 75.3%              | 67.5%     | 60.9%       | 63.1%               | 83.7%          | 89.4%             | 95.0%     |           |       |
|                         | 69.0%                     | 60.0%                  | 50.9%         | 60.3%              | 61.4%     | 54.3%       | 57.9%               | 67.3%          | 74.7%             | 78.0%     | -         |       |
|                         | CA                        | UT                     | CO            | NE                 | MO        | KY          | WV                  | VA             | MD                | СТ        | RI        |       |
|                         | 82.2%                     | 71.5%                  | 78.7%         | 69.6%              | 65.6%     | 65.6%       | 64.4%               | 84.8%          | 85.3%             | 94.3%     | 95.0%     |       |
|                         | 70.9%                     | 63.6%                  | 69.5%         | 62.8%              | 55.4%     | 56.8%       | 57.0%               | 72.3%          | 74.4%             | 78.2%     | 81.2%     |       |
|                         |                           | AZ                     | NM            | KS                 | AR        | TN          | NC                  | SC             | DC                | DE        |           |       |
|                         |                           | 71.9%                  | 86.4%         | 73.8%              | 66.0%     | 61.6%       | 82.8%               | 67.0%          | 95.0%             | 82.1%     |           |       |
|                         |                           | 60.5%                  | 70.0%         | 60.6%              | 53.8%     | 53.8%       | 59.7%               | 56.4%          | 72.1%             | 68.1%     |           |       |
|                         |                           |                        |               | OK                 | LA        | MS          | AL                  | GA             |                   |           |           |       |
|                         | 1                         |                        |               | 70.3%              | 60.5%     | 59.0%       | 62.1%               | 64.7%          |                   |           |           |       |
| HI                      |                           |                        |               | 56.3%              | 52.9%     | 51.3%       | 50.5%               | 54.0%          |                   |           |           |       |
| 86.8%                   |                           |                        | TX            |                    |           |             |                     | FL             |                   | PR        |           |       |
| 77.6%                   |                           |                        | 71.7%         |                    |           |             |                     | 78.4%          |                   | 95.0%     |           |       |
|                         |                           |                        |               | 60.5%              |           |             |                     |                | 66.2%             | ] [       | 81.9%     |       |
|                         |                           |                        |               |                    |           |             |                     |                |                   |           |           |       |


#### The demographics of US vaccination



Source: <u>CDC</u>, <u>CDC</u>, <u>Our World in Data</u>, TrendMacro calculations

### US deep-dive





0.8

31412022

900.00

800.00

400.00

100bp

90bp

80bp

70bp

60bp

50bp


40bp

30bp

20bp

10bp 0bp

Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

## Recommended reading

As virus data grows, the J.&J. vaccine holds its own.

Apoorva Mandavilli *New York Times* March 16, 2022 Pfizer asks US to allow 4th COVID vaccine dose for seniors Zeke Miller and Lauran Neergaard

AP March 15, 2022


<u>Compromise reached on COVID-19 vaccine</u> <u>intellectual property rights waiver</u> Ashley Furlong *Politico* March 15, 2022

#### Meme of the day


The CDC is now recommending you wear a face mask over your eyes when pumping gas to prevent heart attacks.




Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP





## The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale*



# The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality, log scale*









Source: Covid Act Now, TrendMacro calculations

From Ground Zero to the Rio Grande


Cases: 7-day average and daily Deaths: Daily



Source: Johns Hopkins, TrendMacro calculations




Source: Johns Hopkins, TrendMacro calculations




Patient zero... and then everyone else


Cases: 7-day average and daily Deaths: Daily


Source: Johns Hopkins, TrendMacro calculations




Source: Johns Hopkins, TrendMacro calculations









Impact in the BRICs ex-China Cases: 7-day average and daily Deaths: Daily







Source: Johns Hopkins, TrendMacro calculations